

REMARKS

The amendments to the claims do not introduce new matter within the meaning of 35 U.S.C. §132. Accordingly, the Examiner is respectfully requested to enter the above amendment before examination. If the Examiner has any questions regarding this submission, she is invited to telephone the undersigned attorney.

Respectfully submitted,

NATH & ASSOCIATES PLLC

By: 

Gary M. Nath

Registration No. 26,965

Todd L. Juneau

Registration No. 40,669

Customer No. 34375

Date: April 1, 2004

NATH & ASSOCIATES PLLC
1030 15th Street NW, 6th Floor
Washington, D.C. 20005-1503
(202)-775-8383

TLJ/SMM\PA.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SENN-BILFINGER, et al.

Serial No.: Not yet assigned

Art Unit: Not yet assigned


Filed: April 1, 2004

Examiner: Not yet assigned

For: **PYRANO[2,3-C]IMIDAZO[-1,2-A]PYRIDINE DERIVATIVES
FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS**

Appendix A

1. (Currently amended) A compound of the formula 1



(1)

in which R₁ is methyl or hydroxymethyl,


one of the substituents R2a and R2b is hydrogen and the other is hydroxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy,

one of the substituents R3a and R3b is hydrogen and the other is hydroxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy,

where R2a or R2b on the one hand and R3a or R3b on the other hand are not simultaneously hydroxy,

~~and its salts~~ or a salt thereof.

2. (Currently amended) A compound according to claim 1,
~~characterized by~~ having the formula 1*



(1*)

in which R1 is methyl or hydroxymethyl,

one of the substituents R2a and R2b is hydrogen and the other is hydroxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy,

one of the substituents R3a and R3b is hydrogen and the other is hydroxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy,

where R2a or R2b on the one hand and R3a or R3b on the other hand are not simultaneously hydroxy, ~~and its salts or~~ a salt thereof.

3. (Currently amended) A compound of formula 1* according to claim 2, in which R1 is methyl,

one of the substituents R2a and R2b is hydrogen and the other is methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy,

one of the substituents R3a and R3b is hydrogen and the other is hydroxy, ~~and its salts or~~ a salt thereof.

4. (Currently amended) A compound of formula 1* according to claim 2, in which

R1 is methyl,


one of the substituents R2a and R2b is hydrogen and the other is methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy,

one of the substituents R3a and R3b is hydrogen and the other is methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy, ~~and its salts~~ or a salt thereof.

5. (Currently amended) A compound of formula 1* according to claim 2 ~~[[, 3 or 4]]~~ in which R3b is hydrogen.

6. (Currently amended) A compound of formula 1* according to claim 2 ~~[[, 3 or 4]]~~ in which R2a and R3b are hydrogen.

7. (Currently amended) A compound according to claim 1, ~~characterized by~~ having the formula 1**



(1**)

in which one of the substituents Ra and Rb is hydrogen and the other is methoxy, ethoxy, propoxy, isopropoxy, butoxy, methoxyethoxy or methoxypropoxy ~~and its salts or a~~ salt thereof.

8. (Currently amended) A compound according to claim 1 which is (7R, 8R, 9R)-2,3-Dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydropyrano[2,3-c]imidazo[1,2-a]pyridine ~~and its salts or a~~ salt thereof.

9. (Currently amended) A ~~medicament~~ pharmaceutical composition comprising a compound as claimed in claim 1 and/or a pharmacologically tolerable salt thereof together with customary pharmaceutical auxiliaries and/or excipients.

10. (Currently amended) A method of preventing or treating a gastrointestinal disease in a patient comprising administering to a patient in need thereof a therapeutically effective amount of ~~The use of a compound as claimed in claim 1 and its pharmacologically tolerable salts for the production of medicaments for the prevention~~

~~and treatment of gastrointestinal diseases~~ or a
pharmaceutically acceptable salt thereof.

11. (New) A compound of formula 1* according to claim 3 in which R3b is hydrogen.

12. (New) A compound of formula 1* according to claim 4 in which R3b is hydrogen.

13. (New) A compound of formula 1* according to claim 3 in which R2a and R3b are hydrogen.

14. (New) A compound of formula 1* according to claim 4 in which R2a and R3b are hydrogen.

MAIL STOP APPLICATION
Attorney Docket No.: 25081-Y
Preliminary Amendment

APPENDIX B

In the Specification:

On page 1 of the specification, after the title and before the heading of the first paragraph, please insert the following sentence.

-- This is a Continuation application of U.S. Patent Application 10/182,620 filed October 1, 2002 which is a 371 of PCT/EP01/03510 filed March 28, 2001 which claims priority to European patent application no. 00106690.1 filed March 29, 2000, the contents of which are hereby incorporated by reference in its entirety.--

MAIL STOP APPLICATION
Attorney Docket No.: 25081-Y
Preliminary Amendment

APPENDIX C

In the Specification:

After the last page of the specification and claims, on a separate page, please add the following heading and paragraph as the Abstract of the Disclosure for the patent application filed herewith.

ABSTRACT

Compounds of the formula (I), in which the substituents have the meanings mentioned in the description, are suitable for the prevention and treatment of gastrointestinal diseases.